vs
Side-by-side financial comparison of Absci Corp (ABSI) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $650.0K, roughly 1089.9× Absci Corp). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -4548.0%, a 4567.1% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -2.3%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-29.3M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -14.9%).
Absci Corp is a synthetic biology and AI-powered biotech firm focused on advancing next-generation biologic drug discovery and development. It delivers integrated protein engineering solutions to pharmaceutical and biopharmaceutical partners, enabling faster creation of novel antibodies, therapeutic proteins and other complex biologic candidates to address unmet global medical needs.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
ABSI vs MEDP — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $650.0K | $708.5M |
| Net Profit | $-29.6M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | -4775.5% | 21.6% |
| Net Margin | -4548.0% | 19.1% |
| Revenue YoY | -2.3% | 32.0% |
| Net Profit YoY | -2.0% | 15.5% |
| EPS (diluted) | $-0.19 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $650.0K | $708.5M | ||
| Q3 25 | $378.0K | $659.9M | ||
| Q2 25 | $593.0K | $603.3M | ||
| Q1 25 | $1.2M | $558.6M | ||
| Q4 24 | $665.0K | $536.6M | ||
| Q3 24 | $1.7M | $533.3M | ||
| Q2 24 | $1.3M | $528.1M | ||
| Q1 24 | $898.0K | $511.0M |
| Q4 25 | $-29.6M | $135.1M | ||
| Q3 25 | $-28.7M | $111.1M | ||
| Q2 25 | $-30.6M | $90.3M | ||
| Q1 25 | $-26.3M | $114.6M | ||
| Q4 24 | $-29.0M | $117.0M | ||
| Q3 24 | $-27.4M | $96.4M | ||
| Q2 24 | $-24.8M | $88.4M | ||
| Q1 24 | $-22.0M | $102.6M |
| Q4 25 | -4775.5% | 21.6% | ||
| Q3 25 | -7977.2% | 21.5% | ||
| Q2 25 | -5293.9% | 20.9% | ||
| Q1 25 | -2351.9% | 20.3% | ||
| Q4 24 | -4477.3% | 23.4% | ||
| Q3 24 | -1698.7% | 21.1% | ||
| Q2 24 | -2104.0% | 19.9% | ||
| Q1 24 | -2616.7% | 20.4% |
| Q4 25 | -4548.0% | 19.1% | ||
| Q3 25 | -7594.2% | 16.8% | ||
| Q2 25 | -5155.0% | 15.0% | ||
| Q1 25 | -2234.6% | 20.5% | ||
| Q4 24 | -4358.3% | 21.8% | ||
| Q3 24 | -1610.7% | 18.1% | ||
| Q2 24 | -1948.8% | 16.7% | ||
| Q1 24 | -2447.1% | 20.1% |
| Q4 25 | $-0.19 | $4.65 | ||
| Q3 25 | $-0.20 | $3.86 | ||
| Q2 25 | $-0.24 | $3.10 | ||
| Q1 25 | $-0.21 | $3.67 | ||
| Q4 24 | $-0.26 | $3.67 | ||
| Q3 24 | $-0.24 | $3.01 | ||
| Q2 24 | $-0.22 | $2.75 | ||
| Q1 24 | $-0.22 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $189.4M | $459.1M |
| Total Assets | $216.3M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $144.3M | $497.0M | ||
| Q3 25 | $152.5M | $285.4M | ||
| Q2 25 | $38.0M | $46.3M | ||
| Q1 25 | $47.0M | $441.4M | ||
| Q4 24 | $112.4M | $669.4M | ||
| Q3 24 | $38.2M | $656.9M | ||
| Q2 24 | $42.9M | $510.9M | ||
| Q1 24 | $58.8M | $407.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $189.4M | $459.1M | ||
| Q3 25 | $210.3M | $293.6M | ||
| Q2 25 | $173.4M | $172.4M | ||
| Q1 25 | $198.8M | $593.6M | ||
| Q4 24 | $179.1M | $825.5M | ||
| Q3 24 | $201.3M | $881.4M | ||
| Q2 24 | $221.5M | $763.6M | ||
| Q1 24 | $240.1M | $671.5M |
| Q4 25 | $216.3M | $2.0B | ||
| Q3 25 | $245.0M | $1.8B | ||
| Q2 25 | $209.9M | $1.6B | ||
| Q1 25 | $232.4M | $1.9B | ||
| Q4 24 | $213.6M | $2.1B | ||
| Q3 24 | $235.2M | $2.1B | ||
| Q2 24 | $255.5M | $1.9B | ||
| Q1 24 | $274.9M | $1.8B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-29.2M | $192.7M |
| Free Cash FlowOCF − Capex | $-29.3M | $188.1M |
| FCF MarginFCF / Revenue | -4505.4% | 26.6% |
| Capex IntensityCapex / Revenue | 15.8% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $-94.2M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-29.2M | $192.7M | ||
| Q3 25 | $-25.0M | $246.2M | ||
| Q2 25 | $-16.9M | $148.5M | ||
| Q1 25 | $-21.8M | $125.8M | ||
| Q4 24 | $-17.0M | $190.7M | ||
| Q3 24 | $-20.7M | $149.1M | ||
| Q2 24 | $-16.8M | $116.4M | ||
| Q1 24 | $-17.9M | $152.7M |
| Q4 25 | $-29.3M | $188.1M | ||
| Q3 25 | $-26.0M | $235.5M | ||
| Q2 25 | $-17.1M | $142.4M | ||
| Q1 25 | $-21.9M | $115.8M | ||
| Q4 24 | $-17.0M | $183.0M | ||
| Q3 24 | $-20.8M | $138.5M | ||
| Q2 24 | $-17.2M | $103.5M | ||
| Q1 24 | — | $147.2M |
| Q4 25 | -4505.4% | 26.6% | ||
| Q3 25 | -6876.5% | 35.7% | ||
| Q2 25 | -2883.0% | 23.6% | ||
| Q1 25 | -1854.5% | 20.7% | ||
| Q4 24 | -2554.4% | 34.1% | ||
| Q3 24 | -1221.6% | 26.0% | ||
| Q2 24 | -1352.4% | 19.6% | ||
| Q1 24 | — | 28.8% |
| Q4 25 | 15.8% | 0.6% | ||
| Q3 25 | 254.5% | 1.6% | ||
| Q2 25 | 37.6% | 1.0% | ||
| Q1 25 | 2.1% | 1.8% | ||
| Q4 24 | 3.5% | 1.4% | ||
| Q3 24 | 2.8% | 2.0% | ||
| Q2 24 | 26.2% | 2.4% | ||
| Q1 24 | 0.0% | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABSI
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
